Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 609 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR New plan unveiled to tackle Scotland’s cancer crisis June 16, 2023 EMA Recommends Extension of Indications for Niraparib September 29, 2020 Making Cancer Care More Equitable: A Cancer Survivor’s Story July 12, 2023 This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... March 22, 2019 Load more HOT NEWS Cancer in My Community: The Role of Cancer Screening in Guatemala Can Chemotherapy Drugs Be Designed to Avoid Side Effects? Prize winning early detection research Breast Cancer Survivor Given 12 Months to Live After Left Side...
